Inhibition of leukaemia blast cell motility as a test for specific antibody in acute adult myelogenous leukaemia.
Migration studies of acute myelogenous leukaemia blast cells in autologous diagnostic and remission sera from a series of 11 patients have demonstrated two factors. A factor of less than 70 000 molecular weight appears to potentiate blast cell migration whereas the other of molecular weights 100 000-250 000 inhibits blast cell migration relative to a standard non-immune AB serum. The low molecular weight fraction was found in the serum of patients prior to relapse while the greater molecular weight fraction was possibly an IgG antibody that increased in concentration with length of remission. The inhibitory factor was found in patients following immunotherapy and in one patient who received chemotherapy alone. An inhibitory factor was also consistently found in patients in overt clinical relapse following on remission induction and maintenance therapy.
D000328:Adult; D000906:Antibodies / Q000032:analysis*; D000918:Antibody Specificity; D001853:Bone Marrow / Q000276:immunology*; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D002464:Cell Migration Inhibition; D002470:Cell Survival; D006801:Humans; D007951:Leukemia, Myeloid / Q000276:immunology* / Q000628:therapy; D008263:Macrophage Migration-Inhibitory Factors / Q000032:analysis; D012075:Remission, Spontaneous; D013997:Time Factors; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
D000906:Antibodies; D008263:Macrophage Migration-Inhibitory Factors